Travel grant France
| Reference number | |
| Coordinator | CellProtect Nordic Pharmaceuticals AB |
| Funding from Vinnova | SEK 15 000 |
| Project duration | November 2017 - January 2018 |
| Status | Completed |
| Venture | Travel grant |
| Call | Travel grant for building international consortia |
Important results from the project
CellProtect Nordic Pharmaceuticals (CPNP) is seeking partnering opportunities for the further clinical development of its platform technology, CellProtect, an Advanced Medicinal Product based on autologous ex vivo expanded Natural Killer cells with restored cytotoxic activity. CPNP has been granted Orphan Drug Designation for the treatment of Multiple Myeloma from the EC and are planning to advance the clinical development of Cellprotect and reach the market via accelerated/conditional approval.
Expected long term effects
Communicate the CellProtect project and its recent successes and the clinical development plan forward. Make CellProtectNordicPharmaceuticals visible. Identification of potential stakeholders and partners. Networking with potential collaborators.
Approach and implementation
CPNP was represented by Karin Mellström CEO and Marcus Lagerlöf BD and responsible for the financing procurement process. The Company activly participated in a pitch session and also in several sucessful pre-booked one to one partnering meetings. Therse meeting are activily followed-up and contribute significantly to CPNPs financing procuremnet process.